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Topiramate induces type 3 renal tubular acidosis by
inhibiting renal carbonic anhydrase
Sir,
We report a case of mixed (type 3) renal tubular acidosis
(RTA) associated with the anti-convulsant drug topiramate
used for migraine prophylaxis. A 47-year-old woman
treated with topiramate (150mg/day) since 12 months for
invalidating migraine was referred for a metabolic acidosis
evidenced in a routine blood sampling. She complained
of muscle weakness and bone pain. Clinical examination
showed weight loss (6 kg in 4 months) and joint sensitivity.
Blood analyses confirmed a mild hyperchloraemic metabolic
acidosis (plasma HCO3 , 19.0mEq/l; plasma anion gap,
8mEq/l) with hypokalaemia (3.2mEq/l) and normal renal
function. Plasma HCO3 before topiramate administra-
tion was normal. The urine pH was 6.0 with a positive
urinary anion gap (UAG, þ39mEq/day), positive
2-microglobulinuria (2.1mg/l) and a low urinary citrate
excretion (0.7mM/24 h). Serology and auto-immune markers
were negative. Echography showed no kidney calcifications.
The hyperchloraemic metabolic acidosis with normal glomer-
ular filtration rate (GFR) and positive UAG indicates RTA,
associated with both proximal (2-microglobulinuria) and
distal (hypocitraturia) tubular dysfunction. The normal
blood analyses before the introduction of topiramate
suggests that these disorders result from tubular dysfunction
caused by inhibition of carbonic anhydrase (CA).
Type II CA (CAII) plays an essential role in the
reabsorption of ultrafiltered HCO3 by the proximal tubule
(PT) and the net urinary acidification by -type intercalated
cells of the distal nephron (Figure 1). It also provides the Hþ
for extracellular acidification during bone resorption by
osteoclasts. Deficiency in CAII, either inherited (marble
brain disease; OMIM #259730) or acquired (e.g. acetazola-
mide-induced), is associated with a mixed proximal and distal
RTA (type 3 RTA), without evidence for generalized PT
dysfunction [1,2]. Topiramate is a sulfamate-substituted
monosaccharide that is structurally related to acetazolamide
(Figure 1). As such, it inhibits CAII more effectively than
other isoforms [3]. Long-term inhibition of CAII by























































Fig. 1. Role of CA isoforms in the kidney and structure of topiramate. (A) Pathways involved in HCO3 reabsorption and H
þ secretion in PT
cells and -type intercalated cells of the collecting ducts, respectively. Cytosolic type II CA is distributed in both cell types. Note that PT cells
also express type IV CA in the apical brush border and basolateral membrane. (B) Comparative structure of topiramate and acetazolamide.
Both molecules present a sulfonamide group responsible for the inhibition of CA activity.
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proximal and distal tubules, leading to a mixed form of RTA.
By extension, it may also affect bone resorption, leading to
bone pain [4].
The main adverse effects of topiramate include ataxia,
impaired concentration, confusion, dizziness, fatigue and
weight loss. An increased incidence of nephrolithiasis has
been reported, in relation with defective urinary acidifica-
tion and hypocitraturia [5]. Although non-anion gap meta-
bolic acidosis was initially considered as a rare complication
of topiramate, it may actually be more frequent than
expected, particularly in children [5,6]. The plasma HCO3
levels return to normal when the drug is discontinued [5].
Since the use of topiramate has recently been extended to the
treatment of migraine, clinicians should be aware of its
potential effect on renal tubular functions and monitor
plasma HCO3 and K
þ concentrations as long as the drug is
administered.
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Blood pressure in hypertensives—what is the real value?
Sir,
To date there is still great uncertainity as to the best way
to measure blood pressure (BP). Actually the debate is
focused on the reliability of three techniques: self-made
(SM), nurse-made (NM) and physician-made (PM) BP
readings [1,2].
Recently, we analysed the relationships between SM,
NM and PM readings in a cohort of hypertensives
consecutively referred to our brand new out-patient
clinic from 1 January 2005 to 30 June 2005. Essential
hypertensives on wash-out, without comorbidities, owning
a sphygmomanometer, have been considered. Our policy in
this clinical setting foresees the following steps: At the first
visit, serum levels of creatinine, uric acid and glucose are
assessed. Moreover, after a detailed training on SM reading
followed by the calibration of the sphygmomanometer the
patients are invited to record the reading at home just before
the following visit, scheduled 1 week later. At the second
visit, the patients are approached by the nurse (V.N.) who,
after a 5min sitting rest, takes the NM reading, (average of
three determinations within 3min). Then the physician (L.V.)
measures the PM reading in a blinded fashion.
During the observation period we screened 182 patients
among whom 20 (eight males) met the inclusion criteria.
Average (SD) values of age (years) and serum lab parameters
(mg/dl) were: age 58.2 (9.4), creatinine 0.96 (0.19)mg/dl, uric
acid 4.5 (1.4)mg/dl and glucose 99.1 (13.7)mg/dl. Table 1
reports the systolic, diastolic and mean BP (SBP, DBP and
MBP, respectively) values found during the study.
For all the components of BP, PM values were signifi-
cantly higher than the SM and NM values (one-way analysis
of variance and Tukey’s post-hoc test: P< 0.05). After
stratifying the analysis according to median values of the
lab parameters, the differences between PM, NM and SM
values remained significant only in those patients with serum
levels of uric acid >4.2mg/dl and creatinine >0.97mg/dl.
In the entire cohort of patients, a significant relationship
between the MBPs measured by means of PM reading,
and the serum uric acid levels (R¼ 0.54; P¼ 0.01) was
demonstrated.
According to our findings, we suggest that SM and NM
readings provide more reliable BP values while PM may
suffer from emotional reactions driven by sympathetic
activation. The latter is mostly represented in hypertensives
with higher serum levels of uric acid and creatinine,
confirming, somehow, the suggested close relationship
between the clues of renal damage and the sympathetic
drive in determining hypertension status and target organ
damage [3]. Moreover, our experience underlines the need
to take caution and to evaluate the techniques of BP
measurement, in evaluating or planning clinical trials focused
on hypertension.
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Table 1. Values of blood pressure components found with the
3 different techniques
SBP (mmHg) DBP (mmHg) MBP (mmHg)
SM 131.3 (14.7) 76.3 (11.8) 94.6 (10.9)
NM 131.6 (14.2) 77.4 (10.2) 95.4 (10.2)
PM 135.5 (20.1) 79.7 (11.4) 98.3 (12.9)
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